Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Why Is VolitionRx Limited (VNRX) Stock Down -13.91% Today?

Why Is VolitionRx Limited (VNRX) Stock Down -13.91% Today?

Key Takeaways

  • VolitionRx Limited (VNRX) shares fell 13.91% to $0.198 in Monday's morning session, retreating from Friday's close of $0.230.
  • The primary driver is profit-taking: the stock had jumped 24.66% on Friday, its sharpest one-day advance since August, and traders are now locking in those gains.
  • Secondary pressure comes from structural overhangs that never disappeared — a $2.4 million cash balance, going-concern language in the latest quarterly filing, and a steady drip of at-the-market share sales.
  • There was no fresh company announcement, filing, or analyst action behind Monday's slide; the move is a reversal of Friday's earnings-driven advance rather than a reaction to new information.
  • The decline is company-specific: the broad market is down only modestly and healthcare is marginally higher, so index or sector drift explains almost none of the drop.
  • Volume is running near 0.43 million shares in the first 70 minutes — above the pre-earnings norm but a fraction of Friday's 56.9 million.
  • News Significance Score: 35/100 — Moderate post-earnings news met a move roughly 2.4 times the stock's usual daily swing.
  • For deeper detail on targets, quarterly results, and modeling, explore Price Targets, Earnings, and Forecast pages for this ticker.
  • Readers tracking high-probability setups can review the curated Trending AI Robots list for currently outperforming automated strategies.

Opening Summary

VolitionRx Limited (VNRX) is a Henderson, Nevada-based epigenetics company that commercializes blood tests built on its Nu.Q nucleosome platform, spanning veterinary cancer screening, sepsis-related NETosis assays, and human cancer monitoring. Its shares were changing hands at $0.198 at mid-morning on Monday, down 13.91% from the previous session's close of $0.230, confirming a clear downward direction. No new company news explains the drop. The move is best read as a give-back of Friday's 24.66% post-earnings surge, with the same funding and dilution concerns that have capped previous rallies reasserting themselves.

Profit-Taking After a 25% Post-Earnings Pop

Friday's session was the catalyst that set up Monday. VolitionRx reported third-quarter 2026 results before the bell on Friday, disclosing revenue of roughly $1.6 million against $0.6 million a year earlier — a 157% increase that beat consensus of about $0.7 million. Operating expenses fell 14%, the operating loss narrowed 35% to $3.3 million, and the net loss improved to $3.8 million from $5.4 million. Management also highlighted a letter of intent with Missionpharma, part of the Toyota Tsusho group, aimed at point-of-care sepsis testing in resource-constrained markets, and a French government-funded sepsis program in which the company's assay is the sole biomarker.

Investors rewarded the update with a 24.66% jump to $0.230 on 56.9 million shares, a heavy turnover day for a company this size. That gain left the stock extended in the short term, and Monday's decline is consistent with routine profit-taking. Even after the pullback, shares remain roughly 7% above the $0.1845 close recorded before the results, which frames the session as consolidation rather than a fundamental repricing.

Cash and Dilution Concerns Reassert Themselves

The ceiling on the rally remains financial rather than scientific. VolitionRx ended September with about $2.4 million in cash and used $4.6 million of cash in operations during the quarter, against $15 million over the first nine months of the year. The company has also said its plans do not alleviate substantial doubt about its ability to continue as a going concern, and it remains out of compliance with the NYSE American stockholders' equity listing standard, with time to regain compliance extending into 2027.

That funding picture is being managed by selling equity. VolitionRx raised roughly $5.2 million net through its at-the-market program during the third quarter and issued nearly ten million shares to settle convertible notes. With no revenue guidance for 2026 and management flagging that sales will remain lumpy, investors have repeatedly treated sharp spikes as opportunities to exit. Monday's action fits that pattern precisely.

Market Context and Trading Activity

The move is idiosyncratic. Broad equity benchmarks were down about 1.3% at mid-morning while the healthcare sector traded slightly higher, so the 13.91% decline is driven by stock-specific positioning, not sector sympathy or macro news. Volume tells a similar story: roughly 0.43 million shares changed hands in the first 70 minutes, above the approximately one million shares per session that recent weeks averaged on a full-day basis, but far below Friday's 56.9 million. This looks like post-event churn among retail and short-term traders rather than institutional distribution.

Technically, the stock has slipped back below its 50-day moving average near $0.23 and remains light years from its 200-day average around $1.90. It also lost the $0.20 round-number level during the morning, with the 52-week low of $0.1564, set in late October, the obvious reference point below.

News Significance Score

The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news paired with an extreme, rare price swing. VolitionRx earns 35 out of 100.

The verified news is moderate: a strong revenue beat on a small base, a narrower loss, and a credible commercial partner, but no guidance and no licensing deal signed. The price move is also modest relative to this stock's own behavior. The 13.91% decline was about 2.4 times the 5.8% average absolute daily move of the past 69 sessions, and moves of similar size occurred three times in that stretch — including a 24.66% gain just one session earlier. Solid news and an unremarkable relative swing combine into a mid-range score.

What Comes Next for VNRX

Attention now shifts to catalysts that could convert science into cash. Investors are watching for publication of the peer-reviewed feline lymphoma study, which is a condition for unlocking a $5 million milestone payment, and for the French reimbursement submission for the Nu.Q Lung Cancer test, with routine clinical use targeted for the first half of 2027. Progress on the Missionpharma letter of intent, an IVDR application in Europe, and licensing talks around Capture-Seq technology are also in focus. Fourth-quarter results are expected around late March 2027, with analysts projecting revenue near $0.7 million.

The principal risks are unchanged: a thin cash runway, continued reliance on equity sales, unpredictable revenue recognition, thin analyst coverage, and listing-standard compliance. Any delay to the milestone payment or reimbursement timeline would likely be met with another wave of selling.

Trending AI Robots

Investors looking to systematize their approach can explore Tickeron's Trending AI Robots page. Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but this curated section highlights only those strategies performing strongest under present market conditions. Bots differ widely by strategy logic, holding period, performance metrics, and the symbols they trade, so the list offers a practical starting point for matching a methodology to your own objectives. Review the current leaders and see which setups align with your approach.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: VNRX

VNRX in +5.82% Uptrend, growing for three consecutive days on November 09, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where VNRX advanced for three days, in 146 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where VNRX's RSI Oscillator exited the oversold zone, 26 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 46 cases where VNRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VNRX as a result. In 90 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

VNRX moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VNRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

VNRX broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for VNRX entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.183) is normal, around the industry mean (4.142). P/E Ratio (-0.051) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.767) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. VNRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VNRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -7%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was -12%. POAS experienced the highest price growth at 235%, while STIM experienced the biggest fall at -43%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was 0%. For the same stocks of the Industry, the average monthly volume growth was 13% and the average quarterly volume growth was -13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 49
Price Growth Rating: 60
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 10 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a development stage life sciences company

Industry MedicalNursingServices

Industry
Medical Or Nursing Services
Address
1489 West Warm Springs Road
Phone
+1 512 774-8930
Employees
75
Web
https://www.volition.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.